knowledge -WSS

knowledge

author：comprehensive 2025-09-27 12:57:55 - browse：278

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Multiple sclerosis has subtypes with different best treatments: study

hotspot

WSS

Physician executives need more than on

When women are denied an abortion, their children fare worse than peers

Scientists uncover potential path to treating deadly childhood tumor

Physician executives need more than on

VC firm General Catalyst wants to buy a health system

Four alarming medical procedures we’re glad history forgot

explore

knowledge

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Harvard scientists, with Google, unveil the most detailed brain map ever

Wildfire smoke exposes gaps in outdoor worker protections

A virus, fished out of a lake, may have saved a man’s life

Wildfire smoke exposes gaps in outdoor worker protections

Histogen: Failed biotech offers rare public look inside

Duchenne breakthrough therapy leaves behind pioneering families

Chan Zuckerberg Biohub Chicago to focus on inflammation

As demand for Covid shots wanes, Moderna seeks its next success

Covid silver lining: Unprecedented look at human immune system

leisure time

Florida Supreme Court upholds state's abortion ban

U.K. decision on ALS drug has neurologists, advocates up in arms

Phenylephrine and the overlooked value of the placebo effect

FDA panel signals lack of confidence in Amgen cancer drug data

Chemotherapy drug shortage eases slightly but still widespread

Gut bacteria may contribute to kidney autoimmunity, study finds

Wikipedia

hotspot

hotspot

knowledge